

# Contents

|                                                                            |            |
|----------------------------------------------------------------------------|------------|
| <b>List of Symbols and Abbreviations</b> . . . . .                         | <b>vii</b> |
| <b>1 Introduction</b> . . . . .                                            | <b>1</b>   |
| <b>2 State of the art</b> . . . . .                                        | <b>5</b>   |
| 2.1 Tumour incidence rates . . . . .                                       | 5          |
| 2.2 Available technologies in preclinical settings . . . . .               | 7          |
| 2.3 Endoscopic optical technologies, tested in clinical settings . . . . . | 10         |
| 2.4 Hyper spectral imaging . . . . .                                       | 11         |
| 2.5 Statistical discrimination of healthy and cancerous tissue . . . . .   | 14         |
| 2.6 Optical modelling of tissue . . . . .                                  | 18         |
| <b>3 Objective</b> . . . . .                                               | <b>19</b>  |
| <b>4 Materials and methods</b> . . . . .                                   | <b>23</b>  |
| 4.1 In-vivo multi spectral human study . . . . .                           | 23         |
| 4.1.1 Build up and design of the endoscope . . . . .                       | 23         |
| 4.1.2 Patients . . . . .                                                   | 26         |
| 4.1.3 Data analysis . . . . .                                              | 27         |
| 4.1.4 Parameter studies . . . . .                                          | 45         |
| 4.1.5 Analysis of spatial features . . . . .                               | 48         |
| 4.1.6 Test of intra patient variations . . . . .                           | 49         |
| 4.1.7 Comparison to the state of the art . . . . .                         | 49         |
| 4.1.8 Comparison to medical conditions . . . . .                           | 50         |
| 4.1.9 Analysis in the oesophagus . . . . .                                 | 50         |
| 4.2 Spectral spatial variation . . . . .                                   | 51         |
| 4.2.1 Set-up and patients . . . . .                                        | 51         |
| 4.2.2 Derivation of the SSV . . . . .                                      | 51         |
| 4.2.3 Data analysis and varied parameters . . . . .                        | 52         |
| 4.3 Monte-Carlo study of the effect of mislabelled carcinomas . . . . .    | 52         |
| 4.3.1 Validation of MCS . . . . .                                          | 53         |
| 4.3.2 Simulation of inter patient variations . . . . .                     | 54         |
| 4.3.3 MCS set-up . . . . .                                                 | 58         |
| 4.3.4 Model of mislabelled carcinomas . . . . .                            | 60         |
| 4.3.5 Data analysis . . . . .                                              | 63         |
| 4.4 Murine multi/hyper spectral study . . . . .                            | 63         |
| 4.4.1 Spectral estimation of HSI data . . . . .                            | 64         |
| 4.4.2 Evaluation of spectral estimators . . . . .                          | 67         |

|          |                                                                       |            |
|----------|-----------------------------------------------------------------------|------------|
| 4.4.3    | Endoscopic set-up and procedure . . . . .                             | 67         |
| 4.4.4    | Data analysis . . . . .                                               | 69         |
| <b>5</b> | <b>Results and discussion . . . . .</b>                               | <b>71</b>  |
| 5.1      | In-vivo multi spectral human study . . . . .                          | 71         |
| 5.1.1    | Validation of image correction . . . . .                              | 71         |
| 5.1.2    | Parameter study . . . . .                                             | 78         |
| 5.1.3    | Analysis of spatial features . . . . .                                | 86         |
| 5.1.4    | Test of intra patient variations . . . . .                            | 91         |
| 5.1.5    | Comparison to the state of the art . . . . .                          | 91         |
| 5.1.6    | Comparison to medical conditions . . . . .                            | 93         |
| 5.1.7    | Analysis of carcinomas and pre-carcinomas in the oesophagus . . . . . | 95         |
| 5.2      | Spectral spatial variation . . . . .                                  | 96         |
| 5.3      | Monte-Carlo study of the effect of mislabelled carcinomas .           | 101        |
| 5.3.1    | Validation of MCS . . . . .                                           | 101        |
| 5.3.2    | Simulation of inter patient variations . . . . .                      | 102        |
| 5.3.3    | Effect of mislabelling on carcinoma finding . . . . .                 | 104        |
| 5.4      | Murine multi/hyper spectral study . . . . .                           | 110        |
| 5.4.1    | Evaluation of spectral estimators . . . . .                           | 111        |
| 5.4.2    | Murine multi/hyper spectral study . . . . .                           | 113        |
| <b>6</b> | <b>Summary and conclusion . . . . .</b>                               | <b>119</b> |
| <b>7</b> | <b>Zusammenfassung und Schlussfolgerung . . . . .</b>                 | <b>121</b> |
|          | <b>Bibliography . . . . .</b>                                         | <b>123</b> |